Why Cold Chain Matters for Immunotherapy Medicines
Immunotherapy medicines are monoclonal antibodies, not simple chemicals. Their approved labels require unopened vials to be held between 2°C and 8°C, in the original carton, never frozen and never shaken. Outside that range the antibody can degrade — and the vial looks exactly the same afterwards. This page sets out why temperature matters, what a broken cold chain actually does, and the questions to put to a pharmacy before a vial is paid for. It is written for families buying medicine outside the hospital to bring the cost down.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
Why does temperature matter for an immunotherapy vial?
Because the medicine is a protein, and proteins come apart when they get warm. A checkpoint inhibitor is a monoclonal antibody. It works because of the precise shape it is folded into. Heat unfolds that shape. Freezing shatters it. Once the shape is gone, the antibody can no longer bind the target it was designed for.
This is the difference between a biologic and an ordinary tablet. A paracetamol tablet left in a hot cupboard is still paracetamol. A checkpoint inhibitor left in a hot car may no longer be the medicine printed on the label.
Two things happen to a warmed antibody. Some of it unfolds. Some of the unfolded protein then sticks to other unfolded protein and forms clumps, which is called aggregation. Both reduce how much active medicine is left in the vial. Aggregated protein is also the form the immune system is most likely to notice, which is why regulators treat aggregation as a safety question and not only a potency question.
Freezing causes the same damage by a different route. Ice crystals grow inside the liquid and force the protein out of solution. That is why every checkpoint inhibitor label says do not freeze, and why a frozen vial is not rescued by thawing it. Shaking is on the same list for the same reason: vigorous shaking creates an air-liquid interface that pulls antibodies apart.
The requirement on the approved pack inserts is consistent across the marketed PD-1, PD-L1 and CTLA-4 inhibitors. Unopened vials are stored at 2°C to 8°C, upright, in the original carton to protect them from light. Do not freeze. Do not shake. Once a dose has been diluted into an infusion bag, there is a further in-use hold time, and that one genuinely differs from product to product — the specific pack insert governs it, not a general rule from a web page.
The hard part for a family is this: none of this damage is visible. There is no colour change to look for in most cases, no smell, no taste, no home test. A vial that spent four hours in a bag on a summer afternoon looks identical to one that never left the refrigerator. The only evidence that survives is the temperature record — which is exactly what disappears when a vial travels outside a hospital's supply chain.
Did you know?
A vial does not have to be counterfeit to be worthless. WHO's 2017 review of substandard and falsified medical products estimated that around 1 in 10 medical products in low- and middle-income countries is substandard or falsified — and "substandard" includes genuine, legally made medicine that has degraded, most often because it was stored or transported outside the temperature range printed on its own label. For a refrigerated biologic, that failure leaves no mark on the vial at all.
Where can the cold chain break between the factory and the drip?
At every handover, and mostly at the last one. The regulated part of the chain — manufacturer, importer, licensed distributor, hospital pharmacy — is monitored and documented. The unregulated part is the short trip a family makes with a vial in a bag. That trip has no logger, no record and no accountability.
| Stage | What it needs | What breaks it | Who is accountable |
|---|---|---|---|
| Manufacturer to importer or distributor | Validated 2°C to 8°C shipment with a temperature logger travelling in the box | An unmonitored consignment, or a logger nobody reads on arrival | Manufacturer and importer |
| Distributor to hospital pharmacy | Refrigerated vehicle or a validated cold box, packed so vials never touch a frozen gel pack | An ordinary vehicle in a Hyderabad summer; direct contact with ice | Licensed distributor |
| Storage in the hospital pharmacy | A dedicated pharmacy refrigerator holding 2°C to 8°C, with a written temperature log, an alarm and backup power | A domestic fridge, an overloaded shelf, or a power cut with no record of how long it lasted | Hospital pharmacy |
| Pharmacy to the day-care room | A short transfer with the vial still in its carton, in a cold box if the walk is long | A vial carried loose across a campus in the sun, or left on a counter waiting for a slot | Hospital pharmacy and day-care team |
| Dilution into the infusion bag | Prepared in the pharmacy, mixed by gentle inversion, labelled with the time of preparation | Shaking the vial or the bag; preparing a dose long before the patient arrives | Pharmacy |
| Waiting time before the infusion starts | Given inside the in-use hold time stated on that product's pack insert | A prepared bag sitting through a delay nobody timed | Day-care team |
| A vial bought outside and carried in | The same 2°C to 8°C, unbroken, with a record — which almost never exists on this route | A shopping bag, an auto, a two-hour journey, a home refrigerator door shelf | Nobody. The family carries the loss. |
General handling guidance, as of August 2026, drawn from the approved pack inserts for the marketed checkpoint inhibitors, WHO model guidance on the storage and transport of time- and temperature-sensitive pharmaceutical products (Technical Report Series 961, Annex 9), and the storage conditions required under the Drugs and Cosmetics Rules, 1945. It describes what good practice looks like. It is not a claim about any particular pharmacy, distributor or manufacturer.
What actually happens if the cold chain breaks?
Usually nothing you can see, and that is the problem. A temperature excursion does not spoil a vial the way milk spoils. It quietly removes some of the active medicine. The infusion still runs. The bill is still the same. The dose that reached the patient may not have been the dose that was prescribed.
What follows is not a reason to panic about every minute a fridge door was open. Short, recorded excursions are sometimes acceptable under a product's own stability data. The rule is that the pharmacy and the manufacturer decide that, using the record — not the patient, and not by assumption.
- Reduced potency, invisibly. The clinical effect of an under-strength dose cannot be measured in one patient. There is no blood test that says this cycle was weaker than the last one. It shows up, if at all, as a scan that did not go the way the team expected.
- A wasted cycle, not just a wasted vial. The money is the obvious loss. The time is the larger one. A cycle given with a degraded vial has to be counted as given, and the interval before the next one still applies.
- A theoretical safety question. Aggregated protein is the form the immune system is most likely to react to. This is why regulators treat aggregation seriously, and one more reason a suspect vial should not simply be used up.
- Visible damage sometimes, but not reliably. Particles in the solution, unexpected cloudiness or colour, frost inside the carton, a cracked or leaking vial — any of these should stop an infusion. Their absence proves nothing.
- A frozen vial is finished. Freezing damage is not undone by thawing. A vial that has frozen at any point, including against a gel pack in a badly packed box, should not be used.
- Quarantine, do not improvise. The correct response to a suspected excursion is to set the vial aside, label it with the time and temperature, keep it refrigerated, and let the pharmacy check the record against the manufacturer's stability data before anyone decides.
- Never return it quietly to the fridge. A vial put back without a note becomes indistinguishable from a good one. That single decision is what turns one mishandled vial into an unanswerable question later.
- Report a batch you believe is compromised. CDSCO runs a national drug-quality and spurious-drug helpline on 1800 11 1454, and in Telangana the Drugs Control Administration has a toll-free line on 1800 599 6969. Both accept complaints from patients and families.
Helpline numbers are published by CDSCO and the Telangana Drugs Control Administration and are reproduced here as public safety information, current as of August 2026.
Who immunotherapy is not for, and what this page cannot do
Most people with cancer in India are not candidates for a checkpoint inhibitor at all. These medicines are approved for a defined set of cancers, and within those, eligibility usually turns on the stage of the disease, on what treatment came before, and in several cancers on a biomarker result. Nothing about storage changes who the medicine suits. A perfectly handled vial is still the wrong treatment for the large majority of patients.
Checkpoint inhibitors are also not suitable, without individual specialist assessment, for people with active or uncontrolled autoimmune disease, people taking high-dose immunosuppressive medicines, and organ transplant recipients. They work by lifting a brake on the immune system, which is exactly why those situations call for an oncologist's judgment rather than a general rule from a web page.
This page has limits worth stating plainly too. It is not a way to source vials, and nothing here should be read as encouragement to buy immunotherapy outside a hospital — the opposite, if anything. It is not a price list, and it attaches no CION rate to any named medicine. It makes no comparative quality claim between manufacturers, brands, distributors or pharmacies. It does not say that CION stocks, supplies or dispenses any named product. And it cannot tell you whether one particular vial is still good: only the pharmacy holding the temperature record, working with the manufacturer, can answer that.
What should you ask the pharmacy before you pay?
Nine questions, and none of them are rude. A pharmacy that handles oncology biologics answers all of them from its own records in a couple of minutes. Ask before the money changes hands, because afterwards there is nothing left to verify. Print this section or keep it on your phone.
- Where has this vial been stored since it arrived? The answer should be a specific refrigerator, not a general reassurance.
- Can I see the temperature log for that refrigerator? A pharmacy stocking biologics keeps a record, usually twice daily or from a continuous data logger. Asking to see it is normal.
- What happens during a power cut? Backup power, or a validated cold box and a written excursion procedure. "It has never been a problem" is not a procedure.
- Who supplied it, and in what container? The manufacturer or an authorised distributor, delivered in a refrigerated vehicle or a validated cold box. A vial that arrived by ordinary courier has already been outside the chain.
- Does the batch number and expiry on the invoice match the vial and the carton? One number, three places. This is also the check that protects against relabelled and diverted stock.
- Has this vial ever left the refrigerator, and for how long? Ask it directly. A recorded excursion that was assessed and cleared is far better than a vial with no history.
- Is the carton sealed and intact? The original carton is not packaging waste. It protects the vial from light and carries the batch details that make the vial traceable.
- Who is responsible if this batch is recalled? A hospital pharmacy can trace a batch back to its supplier and act on a CDSCO drug alert. An informal seller cannot, and will not.
- Will the vial be stored here until the infusion? The safest arrangement by far is that the medicine never leaves professional refrigeration between purchase and infusion.
Under the Drugs and Cosmetics Rules, 1945, medicines must be stored under the conditions stated on their label, and premises licensed to stock drugs needing cold storage must hold a refrigerator for that purpose. Asking to see how that is being done is a reasonable question from a paying patient, not an accusation.
If a vial spoils, who carries the loss?
Follow the accountability, not just the price. Every route to a vial has a price attached. Only some of them have somebody standing behind the temperature it was kept at. This table compares the routes on that basis, because for a family stretching to afford treatment, an unreplaceable vial is the expensive outcome — not the higher quotation.
| How the vial reaches the patient | Is there a temperature record? | If it spoils, who replaces it? | Can the batch be traced later? |
|---|---|---|---|
| Hospital pharmacy procures it and stores it until the infusion | Yes — the pharmacy refrigerator log, end to end | Handled inside the hospital's own stock and supplier arrangements | Yes — invoice, batch number and patient record all agree |
| Authorised distributor delivers to the hospital for a named patient | Yes — validated shipper, logger read on arrival | The distributor's supply arrangement with the hospital | Yes |
| Outside retail pharmacy, family carries the vial in | Only up to the counter. Nothing after that | Nobody, once it leaves the shop | Invoice yes; storage history after purchase, no |
| Agent, reseller, marketplace or messaging-app seller | No | Nobody | No |
| Couriered from abroad by a relative or an agent | No — and outside the import licence route as well | Nobody | No |
A general comparison of supply routes as of August 2026. It is not a rate card, it names no company, and it makes no claim about any specific pharmacy or distributor. Whether a particular hospital or supplier replaces a spoiled vial depends on its own written policy — ask for it in writing before you buy.
Is there a cheaper route that keeps the cold chain intact?
Often, yes — and it is the biosimilar route, not the informal one. Families are not wrong to hunt for a lower price. Immunotherapy is among the most expensive things in Indian cancer care, and treatment can run for many months. The question worth asking is which discounts come with a supply chain attached and which ones quietly remove it.
Some Indian prices have genuinely fallen. A nivolumab biosimilar reached the Indian market in January 2026 at manufacturer-announced pricing the company described as roughly a quarter of the reference brand, and the originator's Indian patent protection lapsed in May 2026. Pembrolizumab's protection is expected to begin lapsing around 2028-29, which is likely to move that molecule's pricing later. These are indicative figures, as of August 2026, drawn from manufacturer announcements and published reporting. They are not CION rates and they are not a course price.
A CDSCO-approved biosimilar bought through a hospital pharmacy is a real saving with the cold chain, the invoice and the traceable batch all still in place. If the prescription is for a molecule that has an approved Indian biosimilar, that conversation with the treating oncologist is usually the highest-value one available. Our pages on rituximab biosimilars in India, the original cost story and trastuzumab biosimilars in India show how far prices have moved on the two molecules with the longest Indian biosimilar history, and switching from an originator to a biosimilar mid-treatment covers what changes, and what does not, if the switch happens partway through a course.
Three practical points for anyone budgeting. A vial price is not a course price — dosing, weight, cycle interval and the number of cycles all decide the total. Scheme ceilings under Aarogyasri, CGHS, ECHS or ESI, insurer settlements and hospital procurement rates all differ from any published list price. And a written per-cycle estimate from the treating hospital's billing desk is worth more than any figure on a web page, including this one.
One more thing worth being blunt about. If the reason for looking outside the hospital is that the treatment is simply unaffordable, that is a conversation to have with the treating oncologist, not with a reseller. Dose intervals, scheme cover, trial eligibility and the honest question of whether immunotherapy is the right use of a family's savings are all things a medical oncologist can discuss openly. A degraded vial bought at a discount answers none of them.
Reading further on price, biosimilars and drug safety
- Switching From an Originator to a Biosimilar Mid-Treatment — what a switch changes clinically, what it changes on the bill, and what to record when it happens.
- Rituximab Biosimilars in India: The Original Cost Story — the molecule where Indian biosimilar competition first moved a price, and what it predicts.
- Trastuzumab Biosimilars in India — another refrigerated antibody, another long price history, the same cold-chain rules.
- How to Verify an Immunotherapy Vial Is Genuine — the pack-and-paperwork checklist that sits alongside this one.
- Immunotherapy Medicines Explained — the full reference section this page belongs to, including how pricing and regulatory information here is sourced.
- Immunotherapy at CION — the pillar guide to what immunotherapy is, who it suits, and how it is delivered as day care.
This page is editorial reference content. It is not an offer, a price list, or a recommendation to use any named product, and it makes no comparative quality claim between manufacturers, brands, distributors or pharmacies. Storage and handling guidance is drawn from the approved pack inserts for the marketed checkpoint inhibitors, WHO model guidance on time- and temperature-sensitive pharmaceutical products, and the Drugs and Cosmetics Rules, 1945. Price references are drawn from manufacturer announcements and published reporting, dated, and are indicative only, as of August 2026. They are not CION rates, and CION does not state that it stocks or supplies any named product. Whether an immunotherapy medicine has a role in a particular patient's treatment is a decision for the treating oncologist.